论文部分内容阅读
目的探讨盐酸丙卡特罗口服液(PHOS)联合布地奈德雾化吸入(BI)治疗咳嗽变异性哮喘(CVA)的临床效果。方法选择诊断为CVA的患儿96例,以数字表法随机分成治疗组48例和对照组48例。对照组患儿给予布地奈德雾化吸入,20μg/次,2次/d;治疗组患儿给予PHOS联合布地奈德。治疗14 d后,比较两组用药临床效果和不良反应。结果 (1)咳嗽症状评分方面:两组治疗后比较差异有统计学意义(t=2.98,P<0.05);治疗组治疗前后比较差异有统计学意义(t=2.79,P<0.05);(2)有效率:治疗组为95.0%,对照组为80.0%,差异有统计学意义(P<0.05);(3)Ig E和嗜酸性粒细胞(EOS):治疗后两组血清总Ig E和EOS均较治疗前降低(P<0.05),治疗组低于对照组,差异有统计学意义(P<0.05);(4)不良反应:观察组服用PHOS过程中未见明显不良反应。结论 PHOS联合布地奈德可提高机体抗变应性炎症,改善CVA患儿的临床症状,且未见明显不良反应。
Objective To investigate the clinical efficacy of procaterol hydrochloride oral solution (PHOS) and budesonide inhalation (BI) in the treatment of cough variant asthma (CVA). Methods Ninety-six children diagnosed as CVA were randomly divided into treatment group (n = 48) and control group (n = 48) by digital table method. The control group was given budesonide inhalation, 20μg / time, 2 times / d; the treatment group given PHOS combined budesonide. After 14 days of treatment, the clinical effects and adverse reactions of the two groups were compared. Results (1) In cough symptom score, there was significant difference between the two groups after treatment (t = 2.98, P <0.05); the difference between before and after treatment in the treatment group was statistically significant (t = 2.79, 2) Efficacy: The treatment group was 95.0%, the control group was 80.0%, the difference was statistically significant (P <0.05); (3) Ig E and eosinophils (EOS) (P <0.05); (4) Adverse reactions: There was no obvious adverse reaction in the observation group taking PHOS. Conclusions PHOS combined with budesonide can improve the body anti-allergic inflammation, improve the clinical symptoms of CVA children, and no obvious adverse reactions.